Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

63.37 

2.36 3.9%

as of Mar 05 '21

52 Week Range:

13.85 86.42


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer and 360 gene expression, protein immune profiling, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, nCounter Vantage 3D, miRNA expression, cancer copy number variation, and other gene expression panels. Further, the company offers nCounter-based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; and Astellas Pharma, Inc., as well as the Cancer Therapy Evaluation Program of the National Cancer Institute. The company was founded in 2003 and is headquartered in Seattle, Washington.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 2.73
3.05
1.39
-0.30
1.77
1.68
2.00
growth rate 11.7% -54.4% -100.0% 100.0% -5.1% 19.1%
Earnings BIT -12.77
-10.93
-17.71
-25.60
-46.02
-41.24
-41.18
-38.20
-69.39
-82.70
-88.05
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -2.69
-2.69
-2.69
-2.69
-4.62
-4.62
-4.62
-4.62
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -65.83
-55.88
-66.68
-59.88
-46.60
-42.96
-33.11
-54.45
-19.98
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -131.19
-140.19
-289.60
-166.22
-201.10
-57.72
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -73.58
-63.14
-72.49
-54.27
-79.16
-23.12
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 2.80
2.69
3.26
5.07
3.96
3.13
3.39
3.05
4.73
growth rate -3.9% 21.2% 55.5% -21.9% -21.0% 8.3% -10.0% 55.1%
Quick Ratio 2.06
2.12
2.74
4.50
3.29
2.65
2.70
2.58
4.09
growth rate 2.9% 29.3% 64.2% -26.9% -19.5% 1.9% -4.4% 58.5%
Leverage 2.05
2.29
4.59
10.27
3.41
4.00
2.49
growth rate 11.7% 100.4% 123.8% -66.8% 17.3% -37.8%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 3.11
3.32
8.30
12.59
19.99
22.19
19.56
17.28
27.15
31.10
growth rate 6.8% 149.9% 51.7% 58.8% 11.0% -11.9% -11.7% 57.1% 14.5%
Acct.Payable 4.20
7.35
3.40
3.38
3.24
4.94
4.09
8.64
10.28
5.31
growth rate 74.9% -53.7% -0.6% -4.1% 52.2% -17.1% 111.1% 19.1% -48.3%
Cur.Assets 19.02
31.71
60.70
95.22
82.79
113.79
121.92
131.71
212.61
498.98
growth rate 66.8% 91.4% 56.9% -13.1% 37.4% 7.2% 8.0% 61.4% 134.7%
Total Assets 24.58
37.41
64.40
102.07
92.87
126.37
136.76
147.56
259.75
544.20
growth rate 52.2% 72.2% 58.5% -9.0% 36.1% 8.2% 7.9% 76.0% 109.5%
Cash 10.87
21.69
9.90
17.22
21.86
20.58
26.14
24.36
29.03
411.85
growth rate 99.6% -54.4% 74.0% 26.9% -5.8% 27.0% -6.8% 19.2% 1,318.6%
Inventory 3.50
5.38
2.20
5.44
10.14
13.81
20.06
13.17
19.78
22.96
growth rate 53.9% -59.1% 147.5% 86.2% 36.2% 45.2% -34.3% 50.2% 16.1%
Cur.Liabilities 6.78
11.78
18.60
18.81
20.91
36.38
35.92
43.12
44.99
37.10
growth rate 73.7% 57.9% 1.1% 11.2% 74.0% -1.3% 20.0% 4.3% -17.5%
Liabilities 13.08
27.54
32.90
57.26
72.65
114.07
96.65
110.69
155.60
237.25
growth rate 110.6% 19.5% 74.0% 26.9% 57.0% -15.3% 14.5% 40.6% 52.5%
LT Debt 1.01
9.97
12.20
30.00
41.00
47.37
48.93
58.40
79.95
172.70
growth rate 885.2% 22.4% 145.9% 36.7% 15.5% 3.3% 19.3% 36.9% 116.0%
Equity 31.50
44.81
20.22
12.31
40.11
36.87
104.15
306.95
growth rate 42.3% -54.9% -39.1% 226.0% -8.1% 182.5% 194.7%
Common Shares 8.00
9.00
9.00
8.00
18.00
19.00
20.00
24.00
28.00
35.00
growth rate 12.5% 0.0% -11.1% 125.0% 5.6% 5.3% 20.0% 16.7% 25.0%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 1.90
2.69
0.43
0.76
1.90
3.80
3.99
4.28
4.49
7.89
growth rate 41.5% -84.1% 77.3% 150.3% 99.8% 5.1% 7.3% 4.7% 75.8%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA -38.06
-43.36
-6.08
-51.66
-54.07
-89.42
-81.66
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share -1.76
-2.63
-2.47
-0.45
-2.24
-2.08
-2.63
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 14.89
14.77
0.00
58.64
14.69
30.32
59.37
growth rate -0.8% -100.0% -75.0% 106.4% 95.8%
FCF -13.00
-13.00
-15.00
-32.00
-40.00
-47.00
-10.00
-56.00
-59.00
-97.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 11.70
17.80
22.97
31.40
47.59
62.67
86.49
114.91
106.73
125.57
117.32
growth rate 52.1% 29.1% 36.7% 51.6% 31.7% 38.0% 32.9% -7.1% 17.7% -6.6%
Op.Income -13.00
-10.93
-17.71
-29.30
-46.02
-41.24
-41.18
-38.20
-69.39
-82.70
-88.05
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -12.80
-10.93
-17.71
-29.30
-50.04
-45.42
-46.97
-43.36
-77.15
-40.43
-109.83
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -12.80
-10.93
-17.71
-29.30
-50.04
-45.58
-47.09
-43.56
-77.40
-40.70
-110.08
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -2.14
-1.77
-2.75
-4.44
-2.80
-2.40
-2.34
-1.84
-2.78
-1.18
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 2.60
8.02
10.61
16.40
26.44
36.54
56.24
83.03
70.40
81.53
growth rate 208.6% 32.3% 54.5% 61.2% 38.2% 53.9% 47.6% -15.2% 15.8%
R&D 7.50
8.99
11.64
15.00
19.97
22.20
30.95
41.80
55.87
61.31
growth rate 19.9% 29.4% 28.9% 33.1% 11.2% 39.4% 35.1% 33.7% 9.7%

Quarterly Statements

Item Name Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Earnings BIT -20.71
-22.72
-27.64
-23.76
-17.58
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Acct.Receivable 19.54
27.15
21.22
22.02
25.76
growth rate 39.0% -21.9% 3.8% 17.0%
Acct.Payable 6.72
10.28
8.24
5.21
3.75
growth rate 52.9% -19.9% -36.8% -27.9%
Cur.Assets 178.32
212.61
317.21
299.91
286.97
growth rate 19.2% 49.2% -5.5% -4.3%
Total Assets 220.76
259.75
364.88
346.50
332.82
growth rate 17.7% 40.5% -5.0% -4.0%
Cash 23.44
29.03
155.59
168.44
171.45
growth rate 23.9% 435.9% 8.3% 1.8%
Inventory 19.04
19.78
22.22
25.99
26.16
growth rate 3.9% 12.3% 17.0% 0.7%
Cur.Liabilities 37.67
44.99
35.45
35.38
32.12
growth rate 19.4% -21.2% -0.2% -9.2%
Liabilities 148.17
155.60
229.74
231.81
230.22
growth rate 5.0% 47.7% 0.9% -0.7%
LT Debt 79.19
79.95
164.70
167.31
169.96
growth rate 1.0% 106.0% 1.6% 1.6%
Equity 72.59
104.15
135.13
114.69
102.60
growth rate 43.5% 29.8% -15.1% -10.5%
Common Shares 0.00 0.00 0.00 0.00 0.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Capital Expenditures 0.69
6.05
3.94
1.43
1.44
growth rate 783.7% -34.9% -63.8% 1.2%
Cash From OA -20.73
-19.54
-27.78
-22.36
-20.64
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF -21.41
-25.59
-31.72
-23.78
-22.09
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Sales 30.60
36.93
26.61
22.60
31.85
growth rate 20.7% -28.0% -15.0% 40.9%
Op.Income -20.71
-22.72
-27.64
-23.76
-17.58
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -22.68
24.05
-38.56
-27.06
-21.25
growth rate 100.0% -100.0% 0.0% 0.0%
Net Income -22.75
23.99
-38.62
-27.13
-21.32
growth rate 100.0% -100.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 19.68
22.13
15.59
11.89
17.88
growth rate 12.5% -29.6% -23.7% 50.4%
R&D 15.26
16.19
15.53
13.43
12.32
growth rate 6.1% -4.0% -13.5% -8.3%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (15.81)

YOY Growth Grade:

F (2.90)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -4.62 -26.93 -7.61
EPS / Growth 0.0% -2.35

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 25.0% 50.0%
Future PE 0.00 0.01 33.34
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.